CHA CHING, UP KVA goes

Quote












Seriously??? You really think that Procheive is the roadblock for Makena acceptance?? It's early, but you're up for the "Most Stupid Comment of 2012" Award. Congrats, you have my vote.
 












Anonymous said:
It is really a non-issue. Docs will continue, as always, to use the compounded product from trusted compounded pharmacies that have made it for many years.
Click to expand...

This looks to be the truth. I listened to the conference call and the company only hopes for an 8% market share, which means docs are still mainly using the compounded products.

Time to change the title of this thread to "Boom, down goes the stock".
 






KV Pharmaceutical’s Q4 loss more than 7 times revenue
St. Louis Business Journal by Greta Weiderman, Web Editor
Date: Friday, February 10, 2012, 11:16am CST - Last Modified: Friday, February 10, 2012, 2:49pm CST
Related:Health Care Enlarge Image
Greta Weiderman
Web Editor - St. Louis Business Journal
Email
KV Pharmaceutical Co. KV Pharmaceutical Co.

Latest from The Business Journals

KV Pharmaceutical to pay million settlement
Paying for performance: Express Scripts’ CEO George Paz underpaid at .3 million
FDA: KV's Makena different from compounded forms
Follow this company had a loss of $37.8 million on revenue of $5.1 million during the quarter ended Dec. 31, according to a company filing Thursday with the Securities and Exchange Commission.

The loss was less than the $47.8 million the company lost on $3.5 million in revenue during the same quarter in 2010.

According to the SEC filing, there is substantial doubt about the company’s ability to continue as a going concern, and the company expects losses to continue.

Company management listed in the filing seven reasons for the substantial doubt, including the ability to address Food and Drug Administration (FDA) action in regard to Makena drug exclusivity, the ability to obtain sufficient revenue from sales of Makena, the potential outcome of litigation and the ability to comply with debt covenants.

“Our assessment was further affected by our fiscal year 2011 net loss of $271.7 (million) and our net loss of $69.7 (million) for the nine months ended December 31, 2011,” according to the filing.

“If we are not able to obtain the FDA’s approval to resume distribution of more of our approved products in a timely manner and at a reasonable cost, or if revenues from the sale of approved products introduced or reintroduced into the market place prove to be insufficient, our financial position, results of operations, cash flows and liquidity will continue to be materially adversely affected,” the filing states.

In December, the company agreed to pay a $17 million settlement to resolve False Cla ...

KV Pharmaceutical Co. KV Pharmaceutical Co.

Latest from The Business Journals

KV Pharmaceutical to pay million settlement
Paying for performance: Express Scripts’ CEO George Paz underpaid at .3 million
FDA: KV's Makena different from compounded forms
Follow this company had a loss of $37.8 million on revenue of $5.1 million during the quarter ended Dec. 31, according to a company filing Thursday with the Securities and Exchange Commission.

The loss was less than the $47.8 million the company lost on $3.5 million in revenue during the same quarter in 2010.

According to the SEC filing, there is substantial doubt about the company’s ability to continue as a going concern, and the company expects losses to continue.

Company management listed in the filing seven reasons for the substantial doubt, including the ability to address Food and Drug Administration (FDA) action in regard to Makena drug exclusivity, the ability to obtain sufficient revenue from sales of Makena, the potential outcome of litigation and the ability to comply with debt covenants.

“Our assessment was further affected by our fiscal year 2011 net loss of $271.7 (million) and our net loss of $69.7 (million) for the nine months ended December 31, 2011,” according to the filing.

“If we are not able to obtain the FDA’s approval to resume distribution of more of our approved products in a timely manner and at a reasonable cost, or if revenues from the sale of approved products introduced or reintroduced into the market place prove to be insufficient, our financial position, results of operations, cash flows and liquidity will continue to be materially adversely affected,” the filing states.

In December, the company agreed to pay a $17 million settlement to resolve False Claims Act allegations that its now defunct subsidiary, Ethex Corp. Ethex Corp.

Latest from The Business Journals

KV Pharmaceutical to pay million settlement
KV Pharmaceutical wraps million generics unit sale to Zydus
KV to sell generics unit to Zydus for M

Follow this company , failed to advise the Centers for Medicare and Medicaid Services that two unapproved products did not qualify for coverage under federal health-care programs.

Several class-action lawsuits have been filed against Bridgeton-based KV Pharmaceutical (NYSE: KV.A) alleging that it misled investors about its pregnancy drug Makena and made public statements that resulted in artificially inflated prices of KV stock.

In October, the company filed a lawsuit in St. Louis County Circuit Court seeking to avoid paying former Chairman and CEO Marc Hermelin about $36.9 million in retirement benefits and legal expenses.

Read Full Article
See CommentsComments
If you are commenting using a Facebook account, your profile information may be displayed with your comment depending on your privacy settings. By leaving the 'Post to Facebook' box selected, your comment will be published to your Facebook profile in addition to the space below.

Most popularMost popular Facebook Twitter Emailed Mobile Syndication KV Pharmaceutical’s Q4 loss more than 7 times revenue
Express Scripts wins $2.4 billion contract from Maryland
Reuters report: FTC will oppose Express Scripts-Medco deal
Saint Louis Science Center cuts expenses, laying off 24
Four Seasons Hotel St. Louis ranked No. 1 by U.S. News
Supervalu to cut 800 corporate and regional jobs
Fidelity to acquire O’Charley’s
See more popular stories »


Don Pritchard commented on Saint Louis Science Center cuts expenses, laying off 24 workers on Saturday, February 11th


Igor Bertanjoli commented on Reuters report: FTC will oppose Express Scripts purchase of Medco on Thursday, February 9th


Jennifer Ann Blankenheim Holtmann commented on Parkway School Board approves up to $9.6 million in cuts on Thursday, February 9th


Pete Self commented on Looking for good news on the economy? Skip this on Thursday, February 9th


Chris Geden commented on City Academy receives $1.5 million for school’s expansion on Thursday, February 9th

Like the St. Louis Business Journal
stlbj@stlbj

January revenue flat at St. Louis-area #casinos http://t.co/QZ73eil4
#McCarthy #hiring for 60 new positions http://t.co/rqZLsUpu
Who went to the event last night? PHOTOS: 40 Under 40 event at the Chase Park Plaza http://t.co/56CFSukS

Four Seasons Hotel St. Louis ranked No. 1 by U.S. News
Cavalia? Here’s the scoop
Supervalu to cut 800 corporate and regional jobs
Reuters report: FTC will oppose Express Scripts-Medco deal
Saint Louis Science Center cuts expenses, laying off 24
Brown Shoe said to have bid on Collective Brands
Fleishman-Hillard on list of Top 50 Cos. for Executive Women
Sign up for email newsletters
See more emailed stories »

Download the free iPhone app
Download the free Android app
Download the free Blackberry app
View mobile site
Learn more about our mobile apps »

RSS Feeds
RSS (Really Simple Syndication) feeds offer another way to get The Business Journals content. See RSS feeds »
Widgets
Widgets let you display The Business Journals news stories on your own website. Our widgets are compatible with any website. See widgets »
Learn more about RSS and syndication »
People See More People

Search and Contact all People
St. Louis JobsOutside Sales Professional-B2B
Datamax | Saint Louis, MO

Senior Systems Engineer
Faith Group LLC | Saint Louis, MO

Associate Vice Chancellor, Human Resources
St. Louis Community College | Saint Louis, MO

Pension Coordinator
Greater St. Louis Construction Laborers' | Saint Louis, MO

Licensing Manager, Staples Promotional Products
Staples, Inc. | Saint Louis, MO

Post a Job | View More Jobs Listings View Local EventsFind opportunities in St. Louis to network, learn about your industry or introduce yourself to the community. View Calendar
Search St. Louis JobsGo

View All St. Louis Jobs Online
News
Industries
Events
People
Research
Purchase
Careers
Contact Us
Help
Services
Book Of Lists
Commercial Property
Local Business Directory
Jobs
myBookofLists
Search
Subscribe to Paper
Subscriptions
Subscribe to Paper
Trial Subscription
Renew subscription
Single copies
Digital edition
Premium content
Subscriber FAQs
Help
Book Of Lists
Change Mailing Address
Tools
Newsletters
Syndication/RSS
Twitter
Mobile
Submit People
Mobile App
LinkedIn Today
About
Advertise
Contact Us
About the paper
About the business journals
Affiliates
Portfolio
Sports Business Journal
SportsBusiness Daily
Sporting News
Mass High Tech
TechFlash
Sustainable Business Oregon
Hemmings Motor News
© 2012 American City Business Journals, Inc. and its licensors. All rights reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of bizjournals.

Use of and/or registration on any portion of this site constitutes acceptance of our User Agreement and Privacy Policy. About our ads.
 
























This company is going be in bankruptcy very very soon. Better sell whatever stock you have left and get something instead of it going to zero. BOD must fire the CEO to give this company a chance to come out of BK.
 






Top Bottom
Back
Quote